Evommune

Evommune EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Evommune (EVMN) as of Oct 28, 2026 is -81.07 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -70.01 M USD — a change of 15.79% (lower).

EBITDA

-81.07 MUSD

YoY

15.79%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Evommune is 2025 -81.07 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Evommune was 2024 -70.01 M USD. It decreases by 15.79% lower compared to the previous year.

The Evommune EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2023
-37.85 M USD
Jan 1, 2024
-70.01 M USD
Jan 1, 2025
-81.07 M USD
The Evommune EBITDA history
YEAREBITDAYoY
-81.07 MUSD+15.79%
-70.01 MUSD+84.97%
-37.85 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Evommune Stock analysis

What does Evommune do? Evommune Inc generates revenue through its research and development activities focused on inflammatory diseases. The company employs a tissue-based approach using skin as a lens to develop transformative medicines in immunology and dermatology. Its primary products are advanced therapeutic solutions for inflammatory conditions, targeting pharmaceutical companies seeking to accelerate drug development. The firm serves the biotechnology and pharmaceutical sectors with its innovative R&D services. The company's business model centers on providing specialized research services to accelerate medicine development. Evommune, Inc. leverages skin tissue insights to uncover new approaches for immunology and dermatology treatments. Its services are purchased by pharmaceutical firms aiming to enhance their drug development pipelines. The firm's R&D focus on inflammatory diseases positions it as a key partner for companies in the biotech industry. Evommune Inc's revenue streams come from contractual R&D services for pharmaceutical clients. The company's tissue-based methodology for inflammatory disease research is its core offering. It develops and delivers research insights that help clients advance their medicine development in immunology and dermatology. The firm's approach targets the biotechnology sector's need for faster, more effective drug development solutions. Evommune is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Evommune stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Evommune is -81.07 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Evommune changed from -70.01 M USD to -81.07 M USD, representing a 15.79% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Evommune since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Evommune historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Evommune

All Key Metrics — Evommune